# Pfizer Raises 2026 Guidance After Q3 Beat, Even as Revenue Stays Flat at $16.58 Billion

*2026-11-04 07:00 UTC · Business · 1 min read*

> Pfizer posted adjusted EPS of $0.87 against $0.73 expected and lifted full-year revenue guidance to $62-64 billion.

Pfizer reported third-quarter adjusted earnings of $0.87 per share, well above the $0.73 analysts expected, on revenue of $16.58 billion, roughly flat year over year but ahead of the $15.87 billion forecast. GAAP net income fell to $3.24 billion, or $0.56 per share, from $3.54 billion a year earlier.

The company raised its 2026 revenue guidance to $62-64 billion from $60.5-62.5 billion and adjusted EPS to $2.95-$3.05 from $2.80-$3.00, a range that absorbs a one-time $650 million charge (about $0.10 per share) tied to the Innovent Biologics licensing deal. Eliquis sales rose 25% to $2.52 billion, Padcev reached $720 million, and newly launched and acquired products brought in $3.8 billion, up 32% operationally. Comirnaty ($808 million) and Paxlovid ($449 million) both beat estimates.

Pfizer targets about $9.7 billion in net cost savings through 2029 and is leaning on acquisitions, new cancer drugs and the Metsera weight-loss deal for growth. Cecile Guegan became CFO this month after Dave Denton left for Nike.

## Sources

- [cnbc.com](https://www.cnbc.com/2026/11/03/pfizer-pfe-earnings-q3-2026.html)

---
TechTools News · https://techtools.cz/tools/news/article/2633-pfizer-raises-2026-guidance-after-q3-beat-even-as-revenue-stays-flat-at-16-58
Česká verze: https://techtools.cz/tools/news/clanek/2707-pfizer-zvysuje-vyhled-na-rok-2026-po-prekonani-odhadu-za-3-ctvrtleti-trzby